Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole

被引:113
作者
Jelovac, D
Sabnis, G
Long, BJ
Macedo, L
Goloubeva, OG
Brodie, AMH
机构
[1] Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, Hlth Sci Facil 1, Baltimore, MD 21201 USA
[2] Univ Maryland, Greenebaum Canc Ctr, Div Biostat, Baltimore, MD 21201 USA
关键词
D O I
10.1158/0008-5472.CAN-04-4502
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovariectomized mice bearing tumor xenografts grown from aromatase-transfected estrogen receptor (ER)-positive human breast cancer cells (MCF-7Ca) were injected s.c. with 10 mu g/d letrozole for up to 56 weeks. Western blot analysis of the tumors revealed that ERs (ER alpha) were increased at 4 weeks but decreased at weeks 28 and 56. Expression of erbB-2 and p-Shc increased throughout treatment, whereas growth factor receptor binding protein 2 (Grb2) increased only in tumors proliferating on letrozole (weeks 28 and 56). In cells isolated from tumors after 56 weeks and maintained as a cell line (LTLT-Ca) in 1 mu mol/L letrozole, ER alpha was also decreased whereas erbB-2, adapter proteins (p-Shc and Grb2), and the signaling proteins in the mitogen-activated protein kinase (MAPK) cascade were increased compared with MCF-7Ca cells. Growth was inhibited in LTLT-Ca cells but not in MCF-7Ca cells treated with MAPK kinase 1/2 inhibitors U0126, and PD98059 (IC50 similar to 25 mu mol/L). PD98059 (5 mu mol/L) also reduced MAPK activity and increased ER alpha to the levels in MCF-7Ca cells. Epidermal growth factor receptor kinase inhibitor, gefitinib (ZD1839) inhibited growth of LTLT-Ca cells (IC50 similar to 10 mu mol/L) and restored their sensitivity to tamoxifen and anastrozole. In xenografts, combined treatment with ER down-regulator fulvestrant and letrozole, prevented increases in erbB-2 and activation of MAPK and was highly effective in inhibiting tumor growth throughout 29 weeks of treatment. These results indicate that blocking both ER- and growth factor-mediated transcription resulted in the most effective inhibition of growth of ER-positive breast cancer cells.
引用
收藏
页码:5380 / 5389
页数:10
相关论文
共 45 条
[1]   ESTROGEN-DEPENDENT, TAMOXIFEN-RESISTANT TUMORIGENIC GROWTH OF MCF-7 CELLS TRANSFECTED WITH HER2/NEU [J].
BENZ, CC ;
SCOTT, GK ;
SARUP, JC ;
JOHNSON, RM ;
TRIPATHY, D ;
CORONADO, E ;
SHEPARD, HM ;
OSBORNE, CK .
BREAST CANCER RESEARCH AND TREATMENT, 1992, 24 (02) :85-95
[2]   EFFECT OF AN AROMATASE INHIBITOR, 4-HYDROXY-4-ANDROSTENE-3,17-DIONE, ON ESTROGEN-DEPENDENT PROCESSES IN REPRODUCTION AND BREAST-CANCER [J].
BRODIE, AMH ;
SCHWARZEL, WC ;
SHAIKH, AA ;
BRODIE, HJ .
ENDOCRINOLOGY, 1977, 100 (06) :1684-1695
[3]  
BRUNNER N, 1989, CANCER RES, V49, P1515
[4]  
BRUNNER N, 1993, CANCER RES, V53, P3229
[5]   NEW ANTI-OESTROGENIC AGENT IN LATE BREAST CANCER - EARLY CLINICAL APPRAISAL OF ICI46474 [J].
COLE, MP ;
JONES, CTA ;
TODD, IDH .
BRITISH JOURNAL OF CANCER, 1971, 25 (02) :270-&
[6]   AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor [J].
de Mora, JF ;
Brown, M .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (14) :5041-5047
[8]   ENDOMETRIAL CANCER IN TAMOXIFEN-TREATED BREAST-CANCER PATIENTS - FINDINGS FROM THE NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT (NSABP) B-14 [J].
FISHER, B ;
COSTANTINO, JP ;
REDMOND, CK ;
FISHER, ER ;
WICKERHAM, DL ;
CRONIN, WM ;
BOWMAN, D ;
COUTURE, J ;
DIMITROV, NV ;
EVANS, J ;
FARRAR, W ;
KAVANAH, M ;
LICKLEY, HL ;
MARGOLESE, R ;
PATERSON, AHG ;
ROBIDOUX, A ;
SHIBATA, H ;
TERZ, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (07) :527-537
[9]   PLASMA PRECURSORS OF ESTROGEN .2. CORRELATION OF EXTENT OF CONVERSION OF PLASMA ANDROSTENEDIONE TO ESTRONE WITH AGE [J].
HEMSELL, DL ;
GRODIN, JM ;
BRENNER, PF ;
SIITERI, PK ;
MACDONALD, PC .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1974, 38 (03) :476-479
[10]  
James V. H. T., 1980, PROG CANCER RES THER, V14, P471